Radiotherapy for non-small cell lung cancer: evolution and development

doi:10.19401/j.cnki.1007-3639.2020.10.008

China Oncology ›› 2020, Vol. 30 ›› Issue (10): 777-784.doi: 10.19401/j.cnki.1007-3639.2020.10.008

• Specialists’ Commentary and Article • Previous Articles Next Articles

Radiotherapy for non-small cell lung cancer: evolution and development

XU Xinyan ¹ , CHEN Jiayan ¹ , MAO Jingfang ^{1, 2} , FAN Min¹#br#

1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; 2. Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai 201321, China

Online:2020-10-30 Published:2020-11-12
Contact: FAN Min E-mail: fanming@fudan.edu.cn

Abstract

Abstract: Lung cancer is the leading cause of tumor-related death worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Radiotherapy has long been one of the fundamental therapeutic approaches for lung cancer. Over the years, with the ever-accelerated development of radiotherapy technology and the deepened basic and clinical research on NSCLC, the application of radiotherapy in lung cancer treatment has been dramatically expanded, with a promising landscape for future development.

Key words: Lung cancer, Radiotherapy, Progress

XU Xinyan , CHEN Jiayan , MAO Jingfang , FAN Min . Radiotherapy for non-small cell lung cancer: evolution and development[J]. China Oncology, 2020, 30(10): 777-784.

[1]	ZHU Xinzhe, LI Hao, XU Huaxiang, LUO Guopei, YU Xianjun. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021 [J]. China Oncology, 2022, 32(1): 1-12.
[2]	WANG Zezhou , ZHANG Yang , MO Miao , YUAN Jing , ZHOU Changming , SHEN Jie , FENG Xiaoshuang , WU Haoxuan , LI Hang , YE Ting , HU Hong , CHEN Haiquan , ZHENG Ying . Distribution of metastatic sites and survival analysis of patients with non-metastatic lung cancer at initial diagnosis based on hospital registration [J]. China Oncology, 2021, 31(9): 775-782.
[3]	YANG Yanju, ZHONG Yang, HU Weigang, GAO Dadi, ZHAO Jun. Effects of CT-RED calibration curves of different simulators on dose distribution of tumor target and organs at risk [J]. China Oncology, 2021, 31(9): 828-837.
[4]	LU Li, LU Renquan, SUN Jiajun, LU Ning, GUO Lin. The application of serum N-MID in auxiliary diagnosis and therapeutic effect monitoring of bone metastasis in patients with primary lung cancer [J]. China Oncology, 2021, 31(9): 838-844.
[5]	CONG Binbin, WANG Yongsheng. Treatment landscape and challenges of managing the hormone receptor-positive early breast cancer [J]. China Oncology, 2021, 31(8): 689-696.
[6]	ZHU Yihui, LI Ting, HU Xichun. Clinical research progress and prospect of trastuzumab deruxtecan [J]. China Oncology, 2021, 31(8): 754-761.
[7]	GAO Heli, XU Jin, YU Xianjun. Advances in clinical diagnosis and treatment of gastroenteropancreatic neuroendocrine tumor G3 [J]. China Oncology, 2021, 31(7): 567-573.
[8]	LI Haizhou , ZHANG Yanwei , XU Yingjie , YANG Men , ZHANG Lei , HAN Jingjun . miR-933 inhibits proliferation, migration and invasion of lung cancer cell lines by regulation of KLF6 gene [J]. China Oncology, 2021, 31(7): 581-588.
[9]	YANG Jia , LIU Shuyuan , WANG Yingying , LI Yingfu , MA Qianli , LI Yu , WANG Yongrong , LI Chuanyin , TAN Fang . The association of polymorphisms in TNF-α gene with non-small cell lung cancer in Han population of Yunnan Province [J]. China Oncology, 2021, 31(7): 616-628.
[10]	XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia. The advances in immunotherapy biomarkers of small cell lung cancer [J]. China Oncology, 2021, 31(7): 635-639.
[11]	QIAO Tingting , GE Shujing , LUO Yuan , LU Chengrong , DUAN Lianning . Mechanism of inhibition of epithelial-to-mesenchymal transition by phosphorylated H2AX in lung cancer cells [J]. China Oncology, 2021, 31(4): 277-284.
[12]	MU Lina , SU Jia , YU Shunzhang , NIU Rungui , HAN Xiaoyou , LIU Li , SHI Jianping , ZHANG Zuofeng . The control of lung cancer relating to quitting active smoking and secondary smoking: a case-control study of lung cancer in Taiyuan [J]. China Oncology, 2021, 31(4): 335-343.
[13]	YIN Zhihai, WANG Juanqi, MENG Yiran, XU Qing, YANG Zhaozhi. Investigation of patient characteristics associated with setup errors in intensity-modulated radiotherapy after breast-conserving surgery [J]. China Oncology, 2021, 31(3): 198-202.
[14]	YI Weili , ZHAO Wencheng , HUANG Dongning , QIN Li , WU Xintian , ZHOU Fei , WU Fengying . Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer [J]. China Oncology, 2021, 31(3): 203-211.
[15]	ZHAO Yuanyuan , ZHOU Jianying , FAN Yun , WANG Jialei , HUANG Dingzhi , LI Junling , SHI Meiqi , LIU Jiwei , YAO Yu , WU Lin , YAO Wenxiu , ZHANG Li . Advances in the treatment of BRAF V600-mutant non-small cell lung cancer [J]. China Oncology, 2021, 31(12): 1145-1152.

Radiotherapy for non-small cell lung cancer: evolution and development

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments